Agreed dunover, positive pointers except for negligible Evolis sales. We were led to believe almost a decade ago that US sales would reach $100m within 7 years.
Evolis should still be the main brand to promote given its unique hair care features and huge target global market.
Yet the incumbent management continues its flawed obsession on excess M&A. Question why the quest for in house M&A deals now apparently its default stock in trade with beauty products simply camouflage and AN1 as a mere play thing.
Wow, they’ve finally realised the need for a Director of Strategy……part time! The expectation for the grant of 1,000,000 options is a lift in sp to 6 cents.Hopefully that at least arrests the slide in sp having halved and halved again multiple times in recent years.
Agreed dunover, positive pointers except for negligible Evolis...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.481M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1293665 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 332362 | 2 |
View Market Depth
| Last trade - 16.30pm 25/07/2025 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable